HAEMOPHILIA A
Clinical trials for HAEMOPHILIA A explained in plain language.
Never miss a new study
Get alerted when new HAEMOPHILIA A trials appear
Sign up with your email to follow new studies for HAEMOPHILIA A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with hemophilia: safer clotting treatment studied
Disease control CompletedThis study tested a new medicine called N8-GP in 124 young children (under 6 years old) with severe hemophilia A who had never been treated before. The goal was to see if it safely prevents and treats bleeding episodes. The medicine helps blood clot, reducing the risk of bleeds.
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 17, 2026 11:51 UTC
-
New shot Mim8 shows promise for hemophilia a in safety switch study
Disease control CompletedThis study looked at how safe it is for people with hemophilia A to switch from their current medicine (emicizumab) to a new one called Mim8. Mim8 helps prevent bleeding episodes by doing the job of a missing clotting factor. The study included 61 adults and teens who received Mi…
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 17, 2026 11:37 UTC
-
New pen injector could make hemophilia a treatment easier
Disease control CompletedThis study tested a new pen injector for giving the hemophilia A medicine Mim8. The goal was to see if the pen injector delivers the same amount of medicine into the blood as a standard syringe. 205 healthy men received one dose of Mim8 either with the pen or a syringe. The resul…
Matched conditions: HAEMOPHILIA A
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New shot could cut bleeding episodes for hemophilia a patients
Disease control CompletedThis study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those with inhibitors. Mim8 helps replace missing clotting factor to prevent bleeding episodes. Participants received weekly or monthly injections. The goal was to see if Mim8 works …
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for hemophilia: Long-Lasting clotting drug tested in china
Disease control CompletedThis study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe hemophilia A. The drug helps blood clot and was given as an injection to prevent or stop bleeding episodes. The trial lasted about 7-8 months and measured how many bleeds occurred per …
Matched conditions: HAEMOPHILIA A
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hemophilia drug candidate passes first safety check in healthy volunteers
Knowledge-focused CompletedThis study tested a new medicine, Inno8, in 95 healthy men to see if it is safe. Participants received either Inno8 or a placebo as a shot or a pill. The results will help decide if Inno8 should be tested in people with hemophilia A.
Matched conditions: HAEMOPHILIA A
Phase: PHASE1 • Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated May 11, 2026 20:39 UTC